Abstract
Very little progress has been made in the treatment of patients with metastatic squamous cell lung cancer over the past 2 decades. Identification of novel molecular alterations for targeted therapies is necessary to improve outcomes. Advances in genomic technology have now made it possible to analyze the genomic landscape of tumor tissues comprehensively. We summarize here key findings from the comprehensive analysis of squamous cell lung cancer by The Cancer Genome Atlas group and discuss the clinical implications of these findings.
MeSH terms
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use
-
Biomarkers, Tumor / genetics
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / genetics*
-
Carcinoma, Squamous Cell / pathology
-
Databases, Genetic
-
Drug Design
-
Genetic Predisposition to Disease
-
Genome, Human*
-
Genomics
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / pathology
-
Molecular Targeted Therapy
-
Patient Selection
-
Phenotype
-
Precision Medicine
-
Prognosis
-
Signal Transduction / drug effects
-
Signal Transduction / genetics
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor